Patent SG-11201900153X-A (SG)
Title: Androgen receptor antisense oligonucleotides
Inventor: CHUNG SHIN
IPC: C07K14/00
Filed: 2017-05-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#111011110111010101111101 110 100111010H ill Ell 010 1111 11110 MAMIE Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2018/029517 Al 15 February 2018 (15.02.2018) WIP0 I PCT (51) International Patent Classification: 316-1102 Ssangyong Apt. 20, Jungbudae-ro, 788 Beon-gil, C07K 14/00 (2006.01) A61K 38/00 (2006.01) Giheung-gu, Yongin-si, Gyeonggi-do 17077 (KR). JANG, (21) International Application Number: Kangwon; Apt. 1701-1702, Dongbaek8-ro -, Giheung-gu, PCT/IB2017/000697 Yongin-si, Gyeonggi-do 16998 (KR). YOON, Heungsik; 511-2001 Cheonggu Apt. 144, Moojigae-ro, Boondang-gu, (22) International Filing Date: Seongnam-si, Gyeonggi-do 13623 (KR). 24 May 2017 (24.05.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/372,035 08 August 2016 (08.08.2016) US HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant: OLIPASS CORPORATION [KR/KR]; 20th MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, Floor, Ace Dongbaek Tower, 16 Beon-gil, 16-7 Dongbaek PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Jungang-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17015 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (KR). TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — (72) Inventors: CHUNG, Shin; Apt #103-3703, 527 Beon-(84) Designated States (unless otherwise indicated, for every gil 80, Dongbaek Jukjeondae-ro, Giheung-gu, Yon- kind of regional protection available): ARIPO (BW, GH, gin-si, Gyeonggi-do 16990 (KR). JUNG, Daram; The GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Sharp Central-city 1406-1502, 19 Dongtandaerosibeom-gil, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Hwaseong-si, Gyeonggi-do (KR). CHO, Bongjun; TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — = — Title: ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES (54) = Figure 13 = Relative hrightness scores of the \"ASO 5\" treatment groups against the negative control (vehicle) — goup. (statistical analysis by student's t-test) = = = = 115 4 ' Vehicle ..... E \"Aso r 1 im — _ 110 ei 4 \"ASO S.\" 5 Si • \"ASO 5\" 25 SA = 5 _ =i.G = no 6 = : = I uo = a 'C to 7 ,-1 .4 70 8 10 12 14 16 18 ; 2 - Days after Hair Removal IN sl ir) 01 el 0 -- --- GC (57) : Provided are peptide nucleic acid derivatives targeting the 5' splice site of \"exon 5\" within the human androgen receptor , 1 pre-mRNA. The peptide nucleic acid derivatives potently induce splice variants of the androgen receptor mRNA in cells, and are useful 0 to safely treat dermatological indications or conditions involving androgenic activity upon topical administration. N C [Continued on next page] WO 2018/029517 Al MIDEDIMOMMIDIIMERIOTOMMEMOIIIIIIIIIIIIIIIIIII EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, SK, SM, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))